StockData
Lipella Pharmaceuticals Inc. logo

Lipella Pharmaceuticals Inc. (LIPO) company profile

LIPOOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2025, quý kết thúc ngày Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 6/30
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $2.27KP/E –Yield –

About Lipella Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing therapies by reformulating existing generic active pharmaceutical ingredients. The company utilizes a proprietary metastable liposome drug delivery platform designed for local drug application to body cavities lined with endothelial and mucosal surfaces. Its product pipeline includes LP-10 for the treatment of hemorrhagic cystitis, LP-310 for oral lichen planus, LP-410 for oral graft-versus-host disease, and LP-50 for non-muscle invasive bladder cancer. These candidates target patients suffering from severe inflammatory mucosal conditions and treatment-related complications.

The company operates an in-house manufacturing pilot plant to support the development and production of its product candidates. It does not commercialize products or maintain retail stores. Lipella Pharmaceuticals maintains its principal executive offices and headquarters in Pittsburgh, Pennsylvania.

Summary of the business section of Lipella Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Lipella Pharmaceuticals Inc.
Founded
2005
Headquarters
Pittsburgh, PA
Address
400 N Lexington St, Ste Ll103 15208
Phone
(412) 901-0315
Employees
5, Dec 31, 2024
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Urish Popeck & Co., LLC, Pittsburgh, PA

Stock & identifiers

Ticker
LIPO
Exchange
OTC
IPO date
Dec 21, 2022
Shares outstanding
5M, Nov 13, 2025
Public float
$2.62M, Jun 30, 2024
Filer category
<br>Emerging growth company
Stock splits
1-for-8 reverse, Nov 8, 2024
SEC CIK
1347242
CUSIP
53630L209
ISIN
US53630L2097
FIGI
BBG002GP9137
Share class FIGI
BBG002GP9146
LEI
549300NLVVVRGBF0WG69
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jonathan H. KaufmanSee remarks below., Director898,849

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 21, 2022
Offer price
$5.75
Securities offered
1,217,391
Gross proceeds
$7.00M
Exchange
Nasdaq
First trading day
Dec 20, 2022
First-day close
$4.71-18.1%
Lock-up ends (est.)
Jun 18, 2023

“The Offering of the IPO Shares is being made on a firm commitment basis at an initial public offering price of $5.75 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 26, 2025, we had five full-time employees and two part-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?